On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a type of medicine that blocks certain enzymes, for people with advanced or spreading ROS1-posit...
kinase-inhibitor
August 2021: Infigratinib (Truseltiq, QED Therapeutics, Inc.), a kinase inhibitor, has been granted accelerated approval by the Food and Drug Administration for adults with previously treated, unresec...
kinase-inhibitor
August 2021: Tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), a kinase inhibitor, has been approved by the FDA for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after ...
kinase-inhibitor